Core Viewpoint - A federal securities class action lawsuit has been filed against DexCom, Inc. for alleged violations of federal securities laws, primarily related to misleading statements and undisclosed product issues with its G6 and G7 glucose monitoring devices [1][6]. Key Events - **FDA Warning Letter (March 10, 2025)**: The FDA issued a Warning Letter indicating that DexCom had "adulterated" its G6 and G7 sensors by modifying them without prior approval, leading to inaccuracies and health risks. Following this, the stock dropped by $7.12 (−9.15%) to $70.72 [2]. - **Public Disclosure (March 25-26, 2025)**: The FDA published the Warning Letter on its website, confirming product issues, which caused the stock to fall another $3.19 (−4.24%) to $72.13 [2]. - **Oppenheimer Downgrade (September 8, 2025)**: Oppenheimer downgraded DexCom from "outperform" to "perform" due to rising patient concerns over G7 sensor accuracy, resulting in a stock decline of $2.51 (−3.12%) to $78.00 [2]. - **Hunterbrook Report (September 18, 2025)**: A report titled "DexCom's Fatal Flaws" revealed that G7 devices caused hospitalizations and deaths due to inaccurate readings, leading to a stock plunge of $8.99 (−11.76%) to $67.45 over two sessions [2]. Allegations Against DexCom - DexCom allegedly made material design changes to its G6 and G7 devices without FDA authorization, compromising reliability and posing health risks [6]. - The company is accused of overstating the reliability, accuracy, and functionality of the G7 device while downplaying the severity of the issues [6]. - DexCom faces increased risks of regulatory scrutiny, enforcement actions, and financial harm due to these allegations [6]. Next Steps for Investors - Investors who acquired DexCom securities during the class period (July 26, 2024 – September 17, 2025) may move the Court to be appointed lead plaintiff by December 26, 2025 [3].